International Pleuropulmonary Blastoma/DICER1 Registry (for PPB, DICER1 and Associated Conditions)

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Pleuropulmonary blastoma (PPB) is a rare malignant neoplasm of the lung presenting in early childhood. Type I PPB is a purely cystic lesion, Type II is a partially cystic, partially solid tumor, Type III is a completely solid tumor. Treatment of children with PPB is at the discretion of the treating institution. This study builds off of the 2009 study and will also seek to enroll individuals with DICER1-associated conditions, some of whom may present only with the DICER1 gene mutation, which will help the Registry understand how these tumors and conditions develop, their clinical course and the most effective treatments.

Eligibility
Participation Requirements
Sex: All
Maximum Age: 100
Healthy Volunteers: t
View:

• Known or suspected PPB or related thoracic tumor

• Known or suspected sex-cord stromal tumor including Sertoli-Leydig cell tumor and gynandroblastoma (males or females)

• Other known or suspected DICER1-related condition including ovarian sarcoma, cystic nephroma, renal sarcoma, pineoblastoma, pituitary blastoma, nasal chondromesenchymal hamartoma, ciliary body medulloepithelioma and others

• Individuals with known or suspected DICER1 pathogenic variation regardless of whether they have an established DICER1-associated condition

• Informed consent by patient/ or parent/guardian (also, where appropriate: assent and HIPAA consent)

Locations
United States
Minnesota
Children's Minnesota
RECRUITING
Minneapolis
Contact Information
Primary
Kris Ann P Schultz, MD
krisann.schultz@childrensmn.org
612-813-7121
Backup
Paige HR Mallinger, MS
paige.mallinger@childrensmn.org
612-813-7115
Time Frame
Start Date: 2016-12-06
Estimated Completion Date: 2035-12-06
Participants
Target number of participants: 3400
Treatments
Type I PPB
Type I PPB is an early manifestation of this malignant disease, cured in some cases by surgery. Surgical guidelines are presented. It is unknown whether adjuvant chemotherapy improves cure rates for individuals with Type I PPB. If the treating physicians select adjuvant chemotherapy treatment, chemotherapy options include a 22-week regimen: 4 courses of vincristine, actinomycin D and cyclophosphamide (VAC) followed by 3 courses of vincristine and actinomycin D (VA). Therapy decisions are the responsibility of the treating institution.
Types II and III PPB
Types II and III PPB are aggressive sarcomas. Surgery and chemotherapy are necessary in all cases. Surgical guidelines are presented. Many children with Types II or III PPB receive a single-arm multi-agent chemotherapy neo-adjuvant/adjuvant regimen of IVADo (ifosfamide, vincristine, actinomycin, doxorubicin) for 36 weeks. Second and possible 3rd look surgery may be considered for local control. Radiation therapy may be considered. Specific therapy decisions are the responsibility of the treating institution.
Type Ir PPB
Type Ir (regressed) PPB is a unique, purely cystic tumor which lacks a primitive cell component. The International PPB/DICER1 Registry will enroll and follow participants with Type Ir PPB, regardless of age.
DICER1 Gene or Cond Assoc with DICER1
PPB and the associated conditions found in PPB families suggest a familial tendency to formation of tumors. The International PPB/DICER1 Registry for PPB, DICER1 and Associated Conditions study will enroll and follow participants who have the DICER1 gene mutations or conditions associated with PPB or DICER1.
Sponsors
Collaborators: UT Southwestern Medical Center, University of Cambridge, Rutgers Cancer Institute of New Jersey, Huntsman Cancer Institute/ University of Utah, KK Women's and Children's Hospital, Dana-Farber Cancer Institute, Beijing Children's Hospital, Children's Healthcare of Atlanta, Allina Health System, McGill University Health Centre/Research Institute of the McGill University Health Centre, Children's Hospital of Philadelphia, Royal Perth Hospital, Driscoll Children's Hospital, Akron Children's Hospital, ResourcePath, LLC, Federal Scientific Clinical Centre of Pediatric Hematology, Oncology and Immunology named after Dmitry Rogache, Prisma Health-Upstate, Roswell Park Cancer Institute, Ann & Robert H Lurie Children's Hospital of Chicago, University of Virginia, National Institutes of Health (NIH), Connecticut Children's Medical Center, Washington University School of Medicine, Emory University, Phoenix Children's Hospital, Cincinnati Children's Hospital Medical Center (CCHMC), Massachusetts General Hospital, Hannover Medical School, Starship Children's Hospital of New Zealand, The Hospital for Sick Children (SickKids), Louisiana State University Health Sciences Center Shreveport, M.D. Anderson Cancer Center, Kaiser Permanente, Princess Margaret Hospital for Children, Children's Hospital of Los Angeles (CHLA), St. Jude Children's Research Hospital, King Faisal Specialist Hospital & Research Center, Bronson Methodist Hospital, Jewish General Hospital, UC Davis Children's Hospital, Dayton Children's Hospital, University of California, San Francisco, Kingston Health Sciences Centre
Leads: Children's Hospitals and Clinics of Minnesota

This content was sourced from clinicaltrials.gov